Alnylam Pharmaceuticals (NASDAQ:ALNY) Raised to Strong-Buy at Wall Street Zen

Key Points

• Alnylam Pharmaceuticals has been upgraded from a "buy" to a "strong-buy" rating by Wall Street Zen, reflecting increased confidence in the stock's performance.
• Multiple analysts have raised their price targets for Alnylam, with Evercore ISI setting the highest at $515.05, indicating a strong bullish outlook for the stock.
• The company's recent quarterly earnings report showed a significant revenue increase of 17.3% year-over-year, beating consensus estimates by a considerable margin.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a report released on Saturday.

Other equities research analysts also recently issued reports about the company. Evercore ISI upped their price objective on Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the company an "outperform" rating in a research report on Thursday, September 11th. Needham & Company LLC raised their price target on Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the stock a "buy" rating in a research report on Thursday, July 31st. Canaccord Genuity Group lifted their price objective on shares of Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the stock a "buy" rating in a research note on Friday, August 1st. Stifel Nicolaus increased their target price on shares of Alnylam Pharmaceuticals from $441.00 to $495.00 and gave the company a "buy" rating in a research note on Monday, October 6th. Finally, Royal Bank Of Canada lifted their price target on shares of Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the stock an "outperform" rating in a research note on Friday, September 19th. Twenty-three investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $466.92.

Alnylam Pharmaceuticals Trading Down 0.1%

NASDAQ:ALNY opened at $463.43 on Friday. Alnylam Pharmaceuticals has a one year low of $205.87 and a one year high of $495.55. The business has a fifty day moving average price of $459.27 and a 200-day moving average price of $360.03. The firm has a market capitalization of $60.75 billion, a price-to-earnings ratio of -187.62 and a beta of 0.36. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, beating the consensus estimate of ($0.54) by $0.86. The business had revenue of $773.69 million for the quarter, compared to the consensus estimate of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The business's revenue was up 17.3% on a year-over-year basis. During the same period in the previous year, the business earned ($0.13) earnings per share. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Sell-side analysts forecast that Alnylam Pharmaceuticals will post -1.7 EPS for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 8,924 shares of the company's stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total value of $4,034,094.20. Following the completion of the sale, the chief executive officer directly owned 65,409 shares in the company, valued at approximately $29,568,138.45. This represents a 12.01% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Jeffrey V. Poulton sold 3,821 shares of the firm's stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total value of $1,727,283.05. Following the transaction, the executive vice president owned 54,052 shares in the company, valued at approximately $24,434,206.60. This represents a 6.60% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 98,144 shares of company stock worth $44,160,261 over the last quarter. Insiders own 1.50% of the company's stock.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several large investors have recently modified their holdings of ALNY. Salomon & Ludwin LLC bought a new position in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $27,000. ORG Partners LLC lifted its holdings in Alnylam Pharmaceuticals by 70.2% during the third quarter. ORG Partners LLC now owns 80 shares of the biopharmaceutical company's stock worth $36,000 after buying an additional 33 shares during the period. Hilltop National Bank purchased a new stake in Alnylam Pharmaceuticals during the third quarter worth $41,000. Atlantic Union Bankshares Corp bought a new stake in Alnylam Pharmaceuticals during the 2nd quarter valued at $30,000. Finally, SVB Wealth LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 1st quarter valued at $27,000. Institutional investors own 92.97% of the company's stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.